Demetrios P Papahadjopoulos

6410049, Jun 25, 2002

Oct 20, 1999

09/420908

Demetrios Papahadjopoulos - San Francisco CA
Keelung Hong - San Francisco CA
Weiwen Zheng - San Francisco CA

The Regents of the University of California - Oakland CA

A61K 9127

424450, 536 231

The present invention provides for lipid:nucleic acid complexes that have increased shelf life and high transfection activity in vivo following intravenous injection, and methods of preparing such complexes. The methods generally involve contacting a nucleic acid with an organic polycation to produce a condensed nucleic acid, and then combining the condensed nucleic acid with a lipid comprising an amphiphilic cationic lipid to produce the lipid:nucleic acid complex. This complex can be further stabilized by the addition of a hydrophilic polymer attached to hydrophobic side chains. The complex can also be made specific for specific cells, by incorporating a targeting moiety such as an Fabâ fragment attached to a hydrophilic polymer.

6528087, Mar 4, 2003

Jan 16, 2001

09/765107

Demetrios Papahadjopoulos - San Francisco CA
Keelung Hong - San Francisco CA
Weiwen Zheng - San Francisco CA
Dmitri B. Kirpotin - San Francisco CA

The Regents of the University of California - Oakland CA

A61K 9127

424450

The present invention provides for lipid:nucleic acid complexes that have increased shelf life and high transfection activity in vivo following intravenous injection, and methods of preparing such complexes. The methods generally involve contacting a nucleic acid with an organic polycation to produce a condensed nucleic acid, and then combining the condensed nucleic acid with a lipid comprising an amphiphilic cationic lipid to produce the lipid:nucleic acid complex. This complex can be further stabilized by the addition of a hydrophilic polymer attached to hydrophobic side chains. The complex can also be made specific for specific cells, by incorporating a targeting moiety such as an Fabâ fragment attached to a hydrophilic polymer. The present invention further relates to lipidic micro particles with attached proteins which have been first conjugated to linker molecules having a hydrophilic polymer domain and a hydrophobic domain capable of stable association with the microparticle, or proteins which have been engineered to contain a hydrophilic domain and a lipid moiety permitting stable association with the microparticle.

6803053, Oct 12, 2004

Jun 21, 2002

10/177939

Demetrios Papahadjopoulos - San Francisco CA
Keelung Hong - San Francisco CA
Weiwen Zheng - San Francisco CA
Dmitri B. Kirpotin - San Francisco CA

The Regents of the University of California - Oakland CA

A61K 9127

424450, 530411, 530350

The invention provides lipidic microparticles stably associated with at least two different targeting moieties, which targeting moieties are attached to linker molecules comprising a hydrophilic domain and a hydrophobic domain. The targeting moieties can be antibodies, antibody fragments, hormones, growth factors, enzymes, or nucleic acid binding proteins, or other proteins. The targeting moieties can be chemically conjugated to the linker molecules, or they can be fused by recombinant techniques.

6943027, Sep 13, 2005

Apr 12, 2002

10/121962

Demetrios Papahadjopoulos - San Francisco CA, US
Keelung Hong - San Francisco CA, US
Weiwen Zheng - San Francisco CA, US

The Regents of the University of California - Oakland CA

C12N015/88

435458, 514 44

The present invention provides for lipid:nucleic acid complexes that have increased shelf life and high transfection activity in vivo following intravenous injection, and methods of preparing such complexes. The methods generally involve contacting a nucleic acid with an organic polycation to produce a condensed nucleic acid, and then combining the condensed nucleic acid with a lipid comprising an amphiphilic cationic lipid to produce the lipid:nucleic acid complex. This complex can be further stabilized by the addition of a hydrophilic polymer attached to hydrophobic side chains. The complex can also be made specific for specific cells, by incorporating a targeting moiety such as an Fab′ fragment attached to a hydrophilic polymer.

7022336, Apr 4, 2006

May 17, 2004

10/847982

Demetrios Papahadjopoulos - San Francisco CA, US
Keelung Hong - San Francisco CA, US
Weiwen Zheng - San Francisco CA, US
Dmitri B. Kirpotin - San Francisco CA, US

The Regents of the University of California - Oakland CA

A61K 9/127

424450, 435458, 435472

The invention provides methods of attaching proteins to lipidic microparticles with efficiencies of at least 77%. The proteins are attached to linker molecules comprising a hydrophilic domain and a hydrophobic domain. The proteins can be antibodies, antibody fragments, hormones, growth factors, enzymes, or nucleic acid binding proteins, or other proteins. The proteins can be chemically conjugated to the linker molecules, or they can be fused to the linker molecules by recombinant techniques.

7462603, Dec 9, 2008

Apr 4, 2005

11/098888

Demetrios Papahadjopoulos - San Francisco CA, US
Keelung Hong - San Francisco CA, US
Weiwen Zheng - Sa Francisco CA, US

The Regents of the University of California - Oakland CA

A61K 31/713

514 44, 424450, 536 231

The present invention provides for lipid:nucleic acid complexes that have increased shelf life and high transfection activity in vivo following intravenous injection, and methods of preparing such complexes. The methods generally involve contacting a nucleic acid with an organic polycation to produce a condensed nucleic acid, and then combining the condensed nucleic acid with a lipid comprising an amphiphilic cationic lipid to produce the lipid:nucleic acid complex. This complex can be further stabilized by the addition of a hydrophilic polymer attached to hydrophobic side chains. The complex can also be made specific for specific cells, by incorporating a targeting moiety such as an Fab′ fragment attached to a hydrophilic polymer.

7507407, Mar 24, 2009

Oct 11, 2006

11/546781

Christopher C. Benz - Novato CA, US
Demetrios P. Papahadjopoulos - San Francisco CA, US
John W. Park - San Francisco CA, US
Keelung Hong - San Francisco CA, US
Dmitri Kirpotin - San Francisco CA, US

The Regents of the University of California - Oakland CA

A61K 39/395

4241431

The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab′ domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.

7871620, Jan 18, 2011

Feb 12, 2009

12/370038

Christopher C. Benz - Novato CA, US
Demetrios P. Papahadjopoulos - San Francisco CA, US
John W. Park - San Francisco CA, US
Keelung Hong - San Francisco CA, US
Dmitri Kirpotin - San Francisco CA, US

The Regents of the University of California - Oakland CA

A61K 39/395

4241431

The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise an Fab′ domain of an antibody that specifically binds the characteristic marker, an amphipathic vesicle-forming lipid, and a polyethylene glycol derivatized lipid. The invention also provides for growth-inhibiting immunoliposomes that lack growth-inhibiting therapeutic agents and yet are capable of inhibiting the growth and proliferation of target cells.